PureIMS Funding Round

4/4/2023

Venture Equity

Unknown

Undisclosed

The company intends to use the funds to develop lead program Levodopa Cyclops� for US and EEA marketing.

Private & Independent

Biopharmaceutical

Ceintuurbaan Noord 152
Roden, 9301 NZ
NL

PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops�. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company's leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers. PureIMS' lead candidate, Levodopa Cyclops�, is in the final development stage as rescue therapy for OFF-episodes in Parkinson's disease. One product, Colistin Cyclops�, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Other clinical programs --